Theranica

Theranica is a commercial-stage digital therapeutics company pioneering remote electrical neuromodulation (REN) for migraine. Its FDA-authorized and CE-marked Nerivio device is a prescription wearable for acute migraine treatment in adolescents and adults, offering a drug-free alternative. The company is expanding its technology platform into other neurological conditions, such as chronic migraine prevention and other pain disorders. Backed by venture capital, Theranica operates as a private entity, commercializing its device in the US and internationally.

Remote Electrical Neuromodulation (REN): A wearable device that delivers proprietary low-intensity electrical pulses to peripheral nerves in the arm to trigger a conditioned pain modulation response in the brainstem, inhibiting migraine pain pathways. The system is connected to a smartphone app for control, personalization, and data tracking.

Nerivio competes in the acute migraine neuromodulation segment with devices like electroCore's gammaCore (vagus nerve stimulator) and Cefaly (supraorbital transcutaneous stimulator). It also competes indirectly with the entire pharmacological market, including triptans, gepants, and CGRP inhibitors. Its key differentiators are its wearable, discreet form factor, smartphone integration, and arm-based application site.